Oncotarget

Research Papers:

A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer

Xi-Ping Jiang, Xiao-Hui Rui, Cai-Xia Guo, Ya-Qing Huang, Qin Li and Yun Xu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:19125-19136. https://doi.org/10.18632/oncotarget.13253

Metrics: PDF 1109 views  |   HTML 1526 views  |   ?  


Abstract

Xi-Ping Jiang1, Xiao-Hui Rui1, Cai-Xia Guo1, Ya-Qing Huang1, Qin Li1, Yun Xu1

1Department of Gynecology, the First People’s Hospital of Changzhou, Changzhou 213003, P. R. China

Correspondence to:

Yun Xu, email: [email protected]

Keywords: advanced ovarian cancer, chemotherapy, combination therapy, network meta-analysis, bayesian network model

Received: July 28, 2016     Accepted: October 19, 2016     Published: November 09, 2016

ABSTRACT

This study compared the short-term efficacies of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) through pair-wise and network meta-analyses (NMA). Randomized controlled trials (RCTs) identified in a comprehensive online literature search met our inclusion criteria. Direct and indirect evidence was combined to compare odds ratios (OR) and surfaces under the cumulative ranking curves (SUCRA) across the different treatment regimens. Twelve eligible RCTs were finally included, involving eight regimens (Paclitaxel + Carboplatin [PC], Gemcitabine + Carboplatin [GC], Carboplatin, Pegylated Liposomal Doxorubicin + Carboplatin [PLD + Carboplatin], Paclitaxel, Paclitaxel + Carboplatin + Topotecan [PC + Topotecan], Paclitaxel + Carboplatin + Epirubicin [PC + Epirubicin] and Docetaxel + Carboplatin [DC]). The NMA results revealed that in terms of overall response rate (ORR) and disease control rate (DCR), PC (ORR: OR=2.59, 95%CI=1.20–6.22; DCR: OR=2.58, 95%CI=1.05–6.82) and GC (ORR: OR=2.08, 95%CI=1.08–4.37; DCR: OR=2.43, 95%CI=1.07–5.80) were more effective against AOC than Carboplatin alone. Similarly, PC (OR=0.21, 95%CI=0.05–0.69), GC (OR=0.31, 95%CI=0.09–0.90) and PLD + Carboplatin (OR=0.22, 95%CI=0.04–0.92) slowed disease progression better than Carboplatin alone. We also found that PC was more efficacious against AOC than Carboplatin or Paclitaxel single-agent chemotherapy. Combination chemotherapy is thus recommended for AOC, and should guide subsequent drug development and treatment strategies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13253